ED Treatment denied as not FDA-approved for this use by Aetna?
Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Aetna typically requires
Aetna's specific coverage criteria for ed treatment are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Aetna angle on ED Treatment
## Why Aetna Denies ED Treatment as Not FDA-Approved
A "not FDA-approved" denial for an erectile dysfunction treatment typically means one of three things: (1) the specific agent or formulation requested lacks FDA approval for any indication; (2) the requested use is an off-label indication not covered under the plan's off-label drug policy; or (3) Aetna's system flagged the claim because the submitted code did not map cleanly to an approved indication. Understanding which scenario applies to your denial is the first step before responding.
## Why This Denial Is Appealable
If the medication in question carries full FDA approval for the treatment of erectile dysfunction, the denial on "not FDA-approved" grounds is factually contestable and likely overturnable on appeal. Provide the FDA approval documentation directly. If the use is off-label, the appeal shifts to whether the off-label use is supported by recognized clinical evidence — a standard that many plans and state laws require insurers to apply when the off-label use appears in a recognized drug compendium or major medical literature.
## Federal Appeal Framework
- ACA §2719 external review: Available for non-grandfathered plans. An independent external reviewer — not affiliated with Aetna — evaluates whether the denial was proper. The window is typically around four months from the final internal denial; check your letter for the exact deadline.
- ERISA §503: Employer plan participants have statutory rights to a full-and-fair review. Factual errors in a denial (such as a wrong FDA-status finding) are grounds for reversal.
- Expedited review: Request this if delays would seriously harm your health.
## Appeal Process and Timeline
1. Obtain the full denial letter and identify exactly which product and which indication Aetna is claiming lacks FDA approval. 2. Pull the current FDA-approved prescribing information from the FDA's DailyMed database (dailymed.nlm.nih.gov) — this is the authoritative source. 3. Submit a first-level internal appeal with the FDA label and a prescriber letter confirming the approved use. 4. If the denial is for an off-label use, supplement with references to the applicable recognized compendia or clinical practice guidelines. 5. Escalate to external review if the internal appeal is denied.
## Documentation to Gather
- FDA prescribing label: The current full prescribing information for the requested agent, downloaded directly from DailyMed, confirming FDA-approval status and approved indications.
- Prescriber letter: Explicitly stating that the requested use aligns with the FDA-approved indication and explaining the clinical basis for the prescription.
- Diagnosis documentation: Records confirming the patient's diagnosis corresponds to the approved indication.
- Off-label support (if applicable): If the use is off-label, references to major clinical practice guidelines or recognized compendia (AHFS Drug Information, Micromedex, or similar) that support the use.
## Criteria-Mapping Structure
Request Aetna's off-label and coverage policy for this drug class. Then map:
| Aetna Policy Requirement | Your Documentation | |---|---| | [Each criterion from Aetna's policy, copied verbatim] | [FDA label section, guideline citation, or chart record addressing it] |
If Aetna's denial is simply factually wrong about FDA status, lead with that correction plainly and prominently.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →